Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort study using CMS 100% Medicare claims database

References

• Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer J. 2021;11(4):68.
   PubMed Web of Science ®Google Scholar
• Susanibar-Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617–629.
   PubMed Web of Science ®Google Scholar
• American Cancer Society (ACS). Treating non-Hodgkin lymphoma. Atlanta (GA): American Cancer Society (ACS); 2018. p. 1–49.
   Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011(1):498–505.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102(6):1989–1996.
   PubMed Web of Science ®Google Scholar
• Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001;19(2):406–413.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Hao Y, Guerin A, et al. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(5):1133–1142.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA). FDA approves axicabtagene ciloleucel for large B-cell lymphoma. Silver Spring (MD); 2021 [updated 2017 Oct 18; cited 2021 Jul 26]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma
   Google Scholar
• U.S. Food and Drug Administration (FDA). FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. Silver Spring (MD); 2021 [updated 2018 May 1; cited 2021 Jul 26]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma
   Google Scholar
• U.S. Food and Drug Administration (FDA). FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma. Silver Spring (MD); 2021 [updated 2021 Feb 5; cited 2021 Jul 26]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma
   Google Scholar
• Smith S, Essell J. Evolving the delivery of CAR T-cell therapies to the outpatient setting. J Clin Pathways. 2018;4(8):42–47.
   Google Scholar
• Myers GD, Verneris MR, Goy A, et al. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021; 9(4):e002056.
   PubMed Web of Science ®Google Scholar
• YESCARTA^® (axicabtagene ciloleucel) prescribing information. Santa Monica (CA): Kite Pharma, Inc.; 2021.
   Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.
   PubMed Web of Science ®Google Scholar
• Riedell PA, Walling C, Nastoupil LJ, et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas: Oncology Learning Network; 2021 [cited 2021 Jul 26]. Available from: https://www.hmpgloballearningnetwork.com/site/onc/videos/car-t-therapy-efficacy-b-cell-lymphomas-similar-commercial-and-trial-settings
   Google Scholar
• Lyman GH, Nguyen A, Snyder S, et al. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw Open. 2020;3(4):e202072.
   PubMed Web of Science ®Google Scholar
• Stedman MR, Doria-Rose P, Warren JL, et al. The impact of different SEER-Medicare claims-based comorbidity indexes on predicting non-cancer mortality for cancer patients; Bethesda, MD:National Cancer Institute (NCI) 2017 https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html, and the technical report itself can be found at this link: https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity-report.pdf
   Google Scholar
• Riedell PA, Hwang WT, Nastoupil LJ, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2022; 28(10):669–676.
   PubMedGoogle Scholar
• Geethakumari PR, Dhakal B, Ramasamy DP, et al. CAR T-cell therapy: current practice and future solutions to optimize patient access. J Clin Pathways. 2021;7(2):54–62.
   Google Scholar
• Nasta SD, Namoglu EC, Hughes ME, et al. Hospitalization patterns with commercial CAR T-cell therapy: a single institution experience. Blood. 2019;134(Suppl. 1):3240.
   Google Scholar
• Kilgore K, editor. Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization and costs. 61st Annual Meeting and Exposition; 2019 Dec 7–10; 2019. ASH.
   Google Scholar
• Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119–3128.
   PubMed Web of Science ®Google Scholar
• BREYANZI^® (lisocabtagene maraleucel) prescribing information. Bothell (WA): Bristol-Myers Squibb Company; 2021.
   Google Scholar
• KYMRIAH^® (tisagenlecleucel) prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2021.
   Google Scholar
• Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38(27):3095–3106.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Jaglowski S, Hu Z-H, Zhang Y, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) cellular therapy (CT) registry. Blood. 2019;134(Suppl. 1):766.
   Google Scholar
• Pasquini MC, Locke FL, Herrera AF, et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). Washington (DC): American Society of Hematology; 2019.
   Google Scholar
• Topp M, Meerten TV, Houot R, et al. Earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory large B cell lymphoma. Blood. 2019;134(Suppl. 1):243.
   Google Scholar
• Dholaria BR, Bachmeier CA, Locke F. Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities. BioDrugs. 2019; 33(1):45–60.
   PubMed Web of Science ®Google Scholar
• Vitale C, Strati P. CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020;10:849.
   PubMed Web of Science ®Google Scholar
• Myers RM, Kadauke S, Li Y, et al. Risk-adapted preemptive tocilizumab decreases severe cytokine release syndrome (CRS) after CTL019 CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (B-ALL). Biol Blood Marrow Transplant. 2020;26(3):S39.
   Web of Science ®Google Scholar
• American Society of Clinical Oncology. CAR-T therapy policy brief. Alexandria (VA): American Society of Clinical Oncology; 2020. p. 1–4.
   Google Scholar
• American Society of Hematology. CAR T-cell therapy: an update on coverage and reimbursement. Washington (DC); 2019 [cited 2021 Jul 8]. Available from: https://www.hematology.org/advocacy/policy-news/2019/car-t-cell-therapy-an-update-on-coverage-and-reimbursement
   Google Scholar